Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine… Read more
Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.053x
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) has a cash flow conversion efficiency ratio of 0.053x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥425.83 Million) by net assets (CN¥8.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jiangsu Nhwa Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangsu Nhwa Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nextnav Acquisition Corp
NASDAQ:NN
|
0.405x |
|
Coca-Cola Icecek AS
IS:CCOLA
|
0.049x |
|
Tera Yatirim Menkul Degerler A.S.
IS:TERA
|
-0.394x |
|
Shenzhen Kstar Science & Technology Co Ltd
SHE:002518
|
0.079x |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
0.108x |
|
nCino Inc
NASDAQ:NCNO
|
0.005x |
|
Kyushu Railway Company
OTCGREY:KYHHY
|
N/A |
|
Ito En Ltd
PINK:ITOEF
|
0.026x |
Annual Cash Flow Conversion Efficiency for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥7.27 Billion | CN¥916.13 Million | 0.126x | -23.15% |
| 2023-12-31 | CN¥6.41 Billion | CN¥1.05 Billion | 0.164x | +6.30% |
| 2022-12-31 | CN¥5.58 Billion | CN¥861.02 Million | 0.154x | +7.83% |
| 2021-12-31 | CN¥4.90 Billion | CN¥701.12 Million | 0.143x | -52.98% |
| 2020-12-31 | CN¥4.11 Billion | CN¥1.25 Billion | 0.304x | +258.24% |
| 2019-12-31 | CN¥3.60 Billion | CN¥305.97 Million | 0.085x | -37.99% |
| 2018-12-31 | CN¥2.96 Billion | CN¥404.52 Million | 0.137x | -25.53% |
| 2017-12-31 | CN¥2.46 Billion | CN¥452.35 Million | 0.184x | +40.84% |
| 2016-12-31 | CN¥2.12 Billion | CN¥277.14 Million | 0.130x | +16.75% |
| 2015-12-31 | CN¥1.83 Billion | CN¥204.24 Million | 0.112x | -26.13% |
| 2014-12-31 | CN¥1.06 Billion | CN¥160.24 Million | 0.151x | -34.89% |
| 2013-12-31 | CN¥836.21 Million | CN¥194.33 Million | 0.232x | +2.88% |
| 2012-12-31 | CN¥682.44 Million | CN¥154.16 Million | 0.226x | +54.92% |
| 2011-12-31 | CN¥556.01 Million | CN¥81.08 Million | 0.146x | +9.15% |
| 2010-12-31 | CN¥462.56 Million | CN¥61.79 Million | 0.134x | -13.66% |
| 2009-12-31 | CN¥396.00 Million | CN¥61.27 Million | 0.155x | +14.38% |
| 2008-12-31 | CN¥343.75 Million | CN¥46.50 Million | 0.135x | -57.54% |
| 2007-12-31 | CN¥152.39 Million | CN¥48.55 Million | 0.319x | +26.12% |
| 2006-12-31 | CN¥122.67 Million | CN¥30.99 Million | 0.253x | +259.29% |
| 2005-12-31 | CN¥125.74 Million | CN¥8.84 Million | 0.070x | -- |